Tenoclax® - Venetoclax Oral Tablet (10, 50, and 100 mg)

At NanoAlvand, we’re proud to present Venetoclax, a selective BCL-2 inhibitor that has transformed treatment paradigms in hematology. What sets our Venetoclax development apart is the advanced manufacturing technology behind it. We employ Hot-Melt Extrusion (HME), a state-of-the-art process that enhances the solubility and bioavailability of poorly soluble molecules like Venetoclax.

HME is not just a manufacturing method; it requires:

• Sophisticated equipment
• Precise process control
• Deep formulation expertise

By leveraging this capability, NanoAlvand demonstrates its commitment to mastering complex solid dosage forms and delivering innovative therapies to patients while maintaining the highest standards of quality and safety.

Quoted from the FDA label of Venclexta®️ (2023):
“Venetoclax is indicated for the treatment of adults with:
Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
Acute myeloid leukemia (AML), in combination with other agents, in newly-diagnosed patients who are ineligible for intensive chemotherapy.”

With 𝗧𝗲𝗻𝗼𝗰𝗹𝗮𝘅®️, we continue to expand our oncology and hematology portfolio while reaffirming our mission: delivering high-tech, life-changing therapies, because 𝗼𝘂𝗿 𝗛𝗢𝗣𝗘 𝘀𝗵𝗮𝗽𝗲𝘀 𝘁𝗵𝗲 𝗳𝘂𝘁𝘂𝗿𝗲.